The Rise and Fall of Theranos

A Stanford dropout promises to revolutionize blood testing: hundreds of lab results from a single finger-prick drop of blood, at a fraction of the cost. Investors pour in nearly a billion dollars; the valuation peaks around $9 billion; the founder graces magazine covers as the youngest self-made female billionaire. Then the technology fails to work as claimed. Whistleblowers and investigative reporting reveal the devices cannot deliver what was promised. Partnerships collapse, regulators intervene, and by 2018 the company is dissolved. It remains the defining startup fraud of its era — a case study in how charisma, secrecy, and technical opacity can substitute for working technology for years.

Key facts

Founded 2003 by Elizabeth Holmes, promising 240+ tests from a finger-prick
Peak valuation ~$9 billion (2014); raised ~$900M from investors
Core claim: proprietary devices could run comprehensive blood panels — technology never worked as advertised
Exposed by whistleblowers and Wall Street Journal reporting (2015–2016)
Company dissolved 2018; Holmes convicted of fraud January 2022